<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To determine the pathogenetic mechanism underlying the maintenance of arterial narrowing during the <z:hpo ids='HP_0011010'>chronic</z:hpo> phase of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> caused by <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> (SAH), we examined the effect of ozagrel, a <z:chebi fb="0" ids="15627">thromboxane A2</z:chebi> (<z:chebi fb="0" ids="15627">TXA2</z:chebi>) synthetase inhibitor, on <z:hpo ids='HP_0011010'>chronic</z:hpo> vasospasm in a canine two-<z:mp ids='MP_0001914'>hemorrhage</z:mp> model in comparison with that of fasudil, an inhibitor of protein kinases </plain></SENT>
<SENT sid="1" pm="."><plain>The magnitude of the vasospasm was determined angiographically </plain></SENT>
<SENT sid="2" pm="."><plain>On SAH day 7, a vasospasm was observed in every dog </plain></SENT>
<SENT sid="3" pm="."><plain>Intraarterial or intravenous administration of ozagrel (3 mg/kg/30 min) did not reverse the vasospasm but tended to increase <z:mp ids='MP_0001914'>bleeding</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>In contrast, intraarterial administration of fasudil (3 mg/kg/30 min) significantly reversed the vasospasm </plain></SENT>
<SENT sid="5" pm="."><plain>These findings suggest that: 1) <z:chebi fb="0" ids="15627">TXA2</z:chebi> does not participate in the maintenance of <z:hpo ids='HP_0011010'>chronic</z:hpo> vasospasm after SAH; and 2) the protein kinases, particularly myosin-light chain kinase and protein kinase C, are involved in the pathogenesis of arterial narrowing during the <z:hpo ids='HP_0011010'>chronic</z:hpo> phase of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> </plain></SENT>
</text></document>